Inflection Biosciences Ltd

We are developing highly novel therapeutics to address unmet needs in cancer.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Dublin, Ireland
  • Currency EUR
  • Founded January 2012
  • Employees 2
  • Incorporation Type Other
  • Website inflectionbio.com

Company Summary

Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer. IBL-202 is a first-in-class, dual PIM kinase and PI3K inhibitor in development for B-cell malignancies, T-cell lymphoma, acute myeloid leukemia and multiple myeloma. The IBL-100 series comprises selective pan-PIM kinase inhibitors. The partnered pipeline comprises AUM302, a PIM/PI3K/mTOR inhibitor being developed by AUM Biosciences.

Team

  • Co-founder & CEO

    20 years industry experience in life science companies. 8 years at Amarin Corporation plc in a range of senior positions with responsibility covering business and corporate development and investor relations. Prior, Associate Director of Strategic Planning at Elan Corporation plc. Darren holds a B. Comm Degree from NUIG, and Masters in Accountancy from UCD. Trained at PWC and is a Fellow of the Institute of Chartered Accountants in Ireland.

  • Shaun McNulty
    Chief Scientific Officer

    Over 25 years of industry experience. PhD in kinase-mediated signalling in glioma cells, University of York. Held drug discovery leadership positions for Pfizer and GSK. Directed the Syntaxin oncology discovery portfolio, then ImmBio's scientific collaborations. CSO at Biosceptre where he directed a portfolio of oncology candidates, obtaining regulatory approval for two candidates to enter the clinic. Member of the AACR and ASCO.

  • Dr Tess Barker
    Head of Development

    20 years project management experience in the biotech/pharma industry. Worked at companies including KS Biomedix, Microscience and Cambridge Antibody Technology before setting up her own consultancy business. Expertise in the management of oncology projects as they progress through development into initial clinical studies, mostly with virtual or semi-virtual teams. BSc in chemistry, University of York; PhD , University of Birmingham.

Advisors

  • McCann Fitzgerald, Dublin
    Lawyer
    Unconfirmed
    GMC Financial Outsourcing, Dublin
    Accountant
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free